HCPCS Level II code J9277 describes the injectable combination of pembrolizumab and berahyaluronidase alfa-pmph, reported per 1 mg unit; this code represents administration of an oncology biologic with a dispersion enzyme and is typically used for intravenous infusion therapy in hospital outpatient or infusion center settings where monoclonal antibody treatments are delivered.

For related coverage guidance, see recent payer policy updates: Epithelial Cell Cytology in Breast Cancer Risk Assessment, Antibody-Drug Conjugates, Chemotherapy Observation or Inpatient Hospitalization (for New Mexico Only).